About this document

Edoxaban vs Warfarin: Atrial Fibrillation Mortality by Lucas Lincoln is a document available to read on EtoBox.

The ENGAGE AF-TIMI 48 trial found that edoxaban significantly reduced cardiovascular mortality compared to warfarin in patients with atrial fibrillation, primarily due to a lower rate of major bleeding. In total, there were fewer deaths in both higher and lower-dose edoxaban groups compared to warfarin, with a notable reduction in fatal bleeding events. The study highlights the efficacy of edoxaban in improving survival rates through both direct and indirect mechanisms related to bleeding.

Author

Lucas Lincoln

Language

EN